Dr. Moskowitz on the ALCANZA Trial in CTCL

2 Views
administrator
administrator
08/09/23

Alison J. Moskowitz, MD, clinical director, Lymphoma Inpatient Unit, Memorial Sloan Kettering Cancer Center, discusses the data that led to the approval of brentuximab vedotin (Adcetris) in patients with cutaneous T-cell lymphoma (CTCL).

Show more

0 Comments Sort By

No comments found

Facebook Comments

Up next